JP2024506612A5 - - Google Patents

Info

Publication number
JP2024506612A5
JP2024506612A5 JP2023547775A JP2023547775A JP2024506612A5 JP 2024506612 A5 JP2024506612 A5 JP 2024506612A5 JP 2023547775 A JP2023547775 A JP 2023547775A JP 2023547775 A JP2023547775 A JP 2023547775A JP 2024506612 A5 JP2024506612 A5 JP 2024506612A5
Authority
JP
Japan
Prior art keywords
cancer
aforementioned
adenocarcinoma
cell carcinoma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506612A (ja
JP7885229B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/073906 external-priority patent/WO2022170974A1/en
Publication of JP2024506612A publication Critical patent/JP2024506612A/ja
Publication of JP2024506612A5 publication Critical patent/JP2024506612A5/ja
Application granted granted Critical
Publication of JP7885229B2 publication Critical patent/JP7885229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547775A 2021-02-09 2022-01-26 Parp7阻害剤として有用な三環式誘導体 Active JP7885229B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CN2021076144 2021-02-09
CNPCT/CN2021/076144 2021-02-09
CNPCT/CN2021/091050 2021-04-29
CN2021091050 2021-04-29
CNPCT/CN2021/117189 2021-09-08
CN2021117189 2021-09-08
CN2021119368 2021-09-18
CNPCT/CN2021/119368 2021-09-18
CNPCT/CN2021/124714 2021-10-19
CN2021124714 2021-10-19
CN2021128807 2021-11-04
CNPCT/CN2021/128807 2021-11-04
CNPCT/CN2021/129056 2021-11-05
CN2021129056 2021-11-05
PCT/CN2022/073906 WO2022170974A1 (en) 2021-02-09 2022-01-26 Tricyclic derivatives useful as parp7 inhibitors

Publications (3)

Publication Number Publication Date
JP2024506612A JP2024506612A (ja) 2024-02-14
JP2024506612A5 true JP2024506612A5 (cg-RX-API-DMAC7.html) 2025-01-31
JP7885229B2 JP7885229B2 (ja) 2026-07-06

Family

ID=82838260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547775A Active JP7885229B2 (ja) 2021-02-09 2022-01-26 Parp7阻害剤として有用な三環式誘導体

Country Status (11)

Country Link
US (1) US20240336629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291560A4 (cg-RX-API-DMAC7.html)
JP (1) JP7885229B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230167755A (cg-RX-API-DMAC7.html)
CN (1) CN116848114A (cg-RX-API-DMAC7.html)
AU (1) AU2022220924A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210885A1 (cg-RX-API-DMAC7.html)
TW (1) TW202246266A (cg-RX-API-DMAC7.html)
UY (1) UY39625A (cg-RX-API-DMAC7.html)
WO (1) WO2022170974A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
TW202416984A (zh) * 2022-08-17 2024-05-01 大陸商北京加科思新藥研發有限公司 化合物i或其鹽的固體形式
CN117551080A (zh) * 2022-11-11 2024-02-13 杭州师范大学 一种靶向降解parp7的protac化合物及其制备方法与应用
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
AU2024334795A1 (en) * 2023-09-01 2026-04-02 Chongqing Pharscin Innobio Co., Ltd. Parp7 inhibitor and use thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
BR112020022006A2 (pt) * 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN114096533B (zh) * 2019-09-10 2024-03-08 四川科伦博泰生物医药股份有限公司 一种三并环类化合物,包含其的药物组合物,其制备方法及其用途
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof

Similar Documents

Publication Publication Date Title
He et al. WNT/β-catenin signaling in the development of liver cancers
Zheng et al. Lysine demethylase 5B (KDM5B): a potential anti-cancer drug target
Roviello et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments
JP2022548057A5 (cg-RX-API-DMAC7.html)
JP2011521618A5 (cg-RX-API-DMAC7.html)
Jiang CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy
JP2020508302A5 (cg-RX-API-DMAC7.html)
JP2023500483A5 (cg-RX-API-DMAC7.html)
Lau et al. Ciliated muconodular papillary tumor: a solitary peripheral lung nodule in a teenage girl
Espersen et al. Clinical implications of intestinal stem cell markers in colorectal cancer
JP2007153894A5 (cg-RX-API-DMAC7.html)
JP2022153392A5 (cg-RX-API-DMAC7.html)
JP2021520349A5 (cg-RX-API-DMAC7.html)
GEAP202416383A (en) Use of medicament in treatment of tumor disease
Chen et al. Coptidis rhizoma and berberine as anti-cancer drugs: A 10-year updates and future perspectives
RU2016128396A (ru) Новые способы лечения рака
Ke-Chun et al. The role of SPDEF in cancer: promoter or suppressor.
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
JP2024536719A5 (cg-RX-API-DMAC7.html)
JP2023515687A5 (cg-RX-API-DMAC7.html)
JP2025507923A5 (cg-RX-API-DMAC7.html)
JP2013537228A5 (cg-RX-API-DMAC7.html)
WO2006014903A3 (en) Compositions and methods of use for adam12 antagonists in treating disease
JPWO2023048231A5 (cg-RX-API-DMAC7.html)
EP3478293A1 (en) Maintenance therapy for the treatment of cancer